Published in Medical Letter on the CDC and FDA, March 2nd, 2008
There is a great need to develop drugs that target tumors to provide increased efficacy and reduced toxicity. Preliminary results reported in this grant demonstrated that specific polypeptide doxorubicin conjugates showed increased cytoxicity and decreased toxicity when used in conjunction with hyperthermia. This research will be expanded to other drugs and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA